Abstract P1-19-36: Exploratory analysis of TreatER+ight; a Canadian prospective real-world observational study in HR+ advanced breast cancer
Bibliographic record
Abstract
Abstract Background: TreatER+ight is the 1st prospective observational study in Canadian HR+ HER2- advanced breast cancer patients currently receiving endocrine therapy (ET) alone or in combination with targeted therapy (TT) (NCT02753686). Methods: This exploratory analysis displays real-world evidence on baseline demographics, treatment patterns, sequencing, and method of access to therapy. More specifically this abstract focuses on treatment decisions around CDK4/6-based therapy at various lines of treatment. At data cut-off of April 1st 2019, 305 patients were enrolled from 24 sites since Mar'16 with 113 patients receiving CDK4/6is at baseline. 300 patients were evaluable for treatment analysis. Results: Baseline CharacteristicsOverall (n=305)CDK4/6 + ET (n=113)Median age, years (range)67 (23 - 92)67 (23-87)ECOG 0,1,2*95, 104, 1941,32, 4Post-menopausal*21468Pre/peri-menopausal*6530Therapy by disease severity at baselineVisceral (n = 196)Bone only (n = 101)CDK4/6 + ET7338ET5941mTOR + ET6421PI3K + ET01Current therapy on the study Overall (N = 300)CDK4/6 + ET113ET100mTOR + ET86 PI3K + ET1Current CDK therapy by line of treatmentAll CDK4/6 (N = 113)First line60Second line38Third line13 Fourth line2Overall treatment patterns by lineFirst-Line (n = 154)Second-Line (n = 111)Third-Line (n = 64)CDK 4/6i + ET855317ET582711mTOR + Exemestane82114Chemo31022Median duration on therapy in months1L2LCDK4/6 + ET8.87 (median follow-up of 9.6 mos)8.77 (median follow-up of 11.6 mos)*Data missing for some patients at the time of this analysis Conclusions: The majority of patients enrolled (66.6%) are receiving combination therapy with the most common treatment being a CDK4/6-based therapy (56.5%). Of the patients receiving CDK4/6 at baseline a majority are receiving this therapy in the 1L (53.1%) and 2L (33.6%), with the median duration on therapy of respectively 8.87 and 8.77 months. For patients receiving CDK4/6 therapy in 1L, the most common 2L treatment is either endocrine therapy single agent and in certain parts of the country everolimus + exemestane. Further sequencing information will be analyzed and shared for this abstract. Citation Format: Catherine Doyle, Nadia Califaretti, Cristiano Ferrario, Nayyer Iqbal, John Hilton, Theodore Vandenberg, Mihaela Mates, Vivian Glenns, Swati Kulkarni, Puneet Bains, Sina Haftchenary, Sabrina Perri, Stephen Chia. Exploratory analysis of TreatER+ight; a Canadian prospective real-world observational study in HR+ advanced breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-19-36.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.007 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.004 |
| Science and technology studies | 0.002 | 0.001 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".